

MOLECULAR CANCER THERAPEUTICS

TABLE OF CONTENTS

HIGHLIGHTS

- 623** Selected Articles from This Issue

MCT FIRST DISCLOSURES

- 625** **F-aza-T-dCyd (NSC801845), a Novel Cytidine Analog, in Comparative Cell Culture and Xenograft Studies with the Clinical Candidates T-dCyd, F-T-dCyd, and Aza-T-dCyd**

A C Joel Morris, Donn G. Wishka, Omar D. Lopez, Vladimir Rudchenko, Guangfei Huang, Sierra N. Hoffman, Suzanne Borgel, Kyle Georgius, John Carter, Howard Stotler, Mark W. Kunkel, Jerry M. Collins, Melinda G. Hollingshead, and Beverly A. Teicher

REVIEW

- 632** **Role of Polo-Like Kinase 4 (PLK4) in Epithelial Cancers and Recent Progress in its Small Molecule Targeting for Cancer Management**
Debra R. Garvey, Gagan Chhabra, Mary A. Ndiaye, and Nihal Ahmad

SMALL MOLECULE THERAPEUTICS

- 641** **ERK Inhibitor LY3214996-Based Treatment Strategies for RAS-Driven Lung Cancer**
Jens Köhler, Yutong Zhao, Jiaqi Li, Prafulla C. Gokhale, Hong L. Tiv, Aine R. Knott, Margaret K. Wilkens, Kara M. Soroko, Mika Lin, Chiara Ambrogio, Monica Musteanu, Atsuko Ogino, Jihyun Choi, Magda Bahcall, Arrien A. Bertram, Emily S. Chambers, Cloud P. Paweletz, Shripad V. Bhagwat, Jason R. Manro, Ramon V. Tiu, and Pasi A. Jänne
- 655** **Molecular Targeting of RRM2, NF- κ B, and Mutant TP53 for the Treatment of Triple-Negative Breast Cancer**
Elizabeth A. Wilson, Nahid Sultana, Khyati N. Shah, Howard L. Elford, and Jesika S. Faridi

- 665** **ONC201 Shows Potent Anticancer Activity Against Medullary Thyroid Cancer via Transcriptional Inhibition of *RET*, *VEGFR2*, and *IGFBP2***

Rozita Bagheri-Yarmand, Ramona Dadu, Lei Ye, Yaashmin Shiny Jebaraj, Jade A. Martinez, Junsheng Ma, Rohinton S. Tarapore, Joshua E. Allen, Steven I. Sherman, Michelle D. Williams, and Robert F. Gagel

- 676** **PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition-Dependent GSK-3 β -Mediated c-Myc and Pim-1 Proteasomal Degradation**

Mario Scarpa, Prerna Singh, Christopher M. Bailey, Jonelle K. Lee, Shivani Kapoor, Rena G. Lapidus, Sandrine Niyongere, Jaya Sangodkar, Yin Wang, Danilo Perrotti, Goutham Narla, and Maria R. Baer

- 691** **Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma**

Shogo Shigeta, Goldie Y.L. Lui, Reid Shaw, Russell Moser, Kay E. Gurley, Grace Durenberger, Rachele Rosati, Robert L. Diaz, Tan A. Ince, Elizabeth M. Swisher, Carla Grandori, and Christopher J. Kemp

- 704** **Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK**

David K. Lau, Ian Y. Luk, Laura J. Jenkins, Andrew Martin, David S. Williams, Kael L. Schoffer, Fiona Chionh, Michael Buchert, Katrin Sjoquist, Alex Boussioutas, Sarah A. Hayes, Matthias Ernst, Andrew J. Weickhardt, Nick Pavlakakis, Niall C. Tebbutt, and John M. Mariadason

LARGE MOLECULE THERAPEUTICS

- 716** **Anti-LYPD1/CD3 T-Cell-Dependent Bispecific Antibody for the Treatment of Ovarian Cancer**
Amy A. Lo, Jennifer Johnston, Ji Li, Danielle Mandikian, Maria Hristopoulos, Robyn Clark, Dorothee Nickles, Wei-Ching Liang, Kathy Hötzel, Debra Dunlap, Thinh Pham, Hao Cai, Meric Ovacik, Daniel Bravo-Perez, Elaine Mai, Dionysos Slaga, Diego Ellerman, James Ziai, Klara Totpal, Genee Lee, C. Andrew Boswell, Jian Payandeh, Yan Wu, and Teemu T. Junttila

TABLE OF CONTENTS

CANCER BIOLOGY AND TRANSLATIONAL STUDIES

726 Lipidome-based Targeting of STAT3-driven Breast Cancer Cells Using Poly-L-glutamic Acid-coated Layer-by-Layer Nanoparticles

Isidora Tošić, Lisa N. Heppler, Susana P. Egusquiaguirre, Natalie Boehnke, Santiago Correa, Daniel F. Costa, Elizabeth A. Grossman Moore, Sharmistha Pal, Douglas S. Richardson, Alexander R. Ivanov, Daphne A. Haas-Kogan, Daniel K. Nomura, Paula T. Hammond, and David A. Frank

739 V-ATPase Inhibition Decreases Mutant Androgen Receptor Activity in Castrate-resistant Prostate Cancer


AC Bradleigh Whitton, Haruko Okamoto, Matthew Rose-Zerilli, Graham Packham, and Simon J. Crabb

AC AC icon indicates AuthorChoice

For more information please visit www.aacrjournals.org

ABOUT THE COVER

In this issue of *Molecular Cancer Therapeutics*, Morris and colleagues disclose a novel fluorine-containing cytidine analog, F-aza-T-dCyd. F-aza-T-dCyd produced complete regressions in the HL-60 model pictured, as well as in xenografts of bladder and colon cancer. Their disclosure supports the continued development of F-aza-T-dCyd as a new therapeutic in a category that has seen five FDA approvals. Read the full manuscript on page 625.



MODELS AND TECHNOLOGIES

749 Isoform- and Phosphorylation-specific Multiplexed Quantitative Pharmacodynamics of Drugs Targeting PI3K and MAPK Signaling in Xenograft Models and Clinical Biopsies

AC William G. Herrick, Casey L. Kilpatrick, Melinda G. Hollingshead, Dominic Esposito, Geraldine O'Sullivan Coyne, Andrea M. Gross, Barry C. Johnson, Alice P. Chen, Brigitte C. Widemann, James H. Doroshov, Ralph E. Parchment, and Apurva K. Srivastava

Molecular Cancer Therapeutics

20 (4)

Mol Cancer Ther 2021;20:623-760.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/20/4>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/20/4>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.